Concentration, Tariffs, and a SpaceX Wildcard: The MSCI World ETF’s June Tightrope

The ETF's rally to $205.84 is powered by a narrow tech base, but overbought RSI, Fed rate pause, and new tariffs threaten near-term gains.

The iShares MSCI World ETF has stretched to a new high, climbing to 205.84 USD, and mechanical indicators are flashing danger. The relative strength index sits at 94.6 — deep in overbought territory — a technical signal that has historically preceded short-term pullbacks. Yet the fund’s rally rests on an increasingly narrow base of US technology stocks, while several external pressures test whether this record pace can hold.

The underlying index contains 1,308 securities, but the heaviest weights are extreme. Nvidia leads with 5.64 percent, followed by Apple at 5.05 percent and Microsoft at 3.50 percent. Amazon and Alphabet A round out the top five at 2.86 percent and 2.44 percent, respectively. Information technology alone accounts for 30.57 percent of the portfolio — nearly double the allocation to financials and industrials combined. Geographically, US equities dominate at 72.35 percent, with Japan a distant second at 5.66 percent. Germany ranks seventh at 2.16 percent.

That concentration makes the ETF acutely vulnerable to any shock in Big Tech valuations. And the headwinds are building.

The Federal Reserve offers no relief. Kevin Warsh assumed the chair on May 15 and will lead his first policy meeting on June 17. Markets assign a 97 percent probability of a rate pause, and for good reason: US inflation stands at 3.8 percent — a three-year high — while wage growth lags at 3.6 percent. The core PCE index rose 0.4 percent month-on-month in April, and real consumer spending eked out just 0.1 percent growth. Goldman Sachs and Bank of America have both scrapped their rate-cut forecasts for 2026 entirely. For a fund so weighted toward growth stocks, persistently high financing costs compress the valuation multiples that have powered the rally.

Adding to the pressure, the Trump administration has imposed 15 percent tariffs on patented pharmaceutical active ingredients from the European Union, Japan, South Korea, and Switzerland. British products face a 10 percent levy. Companies without existing pricing agreements with Washington are hit with a 100 percent rate. The health-care sector makes up roughly 10 percent of the ETF’s holdings, and FactSet has already lowered earnings expectations for the industry. That is a concrete drag on a fund that has ridden the technology wave.

BlackRock, the issuer, charges a total expense ratio of 0.24 percent — significantly more than Invesco’s comparable product at 0.05 percent. Morningstar still awards the fund a Gold rating, noting a tracking difference of just 0.02 percent. The ETF gathered net inflows of 1.86 billion USD over the past twelve months, and assets under management stand at 8.11 billion USD. As of June 1, the net asset value was 205.38 USD, with the closing price on the NYSE Arca at 205.36 USD — a spread of minus 0.01 percent that underscores tight liquidity. The year-to-date return through May 29 came in at 10.57 percent.

The portfolio’s valuation remains stretched. The trailing P/E ratio is 26.15, the price-to-book multiple stands at 4.07, and the SEC 30-day yield sits at just 1.20 percent. The three-year beta of 0.93 suggests slightly less volatility than the broader market, but the annualised volatility of 12.45 percent is hardly tame.

A potential structural catalyst looms over the summer. SpaceX confidentially filed for an initial public offering in April, and a Nasdaq listing at a valuation around 1.75 trillion USD is expected. MSCI’s chief executive Henry Fernandez has said the stock could be added to MSCI indices just ten trading days after the IPO — waiving the usual three-month lock-up for very large new listings, provided the share price stabilises. Under those fast-track rules, SpaceX could land in the MSCI World within fifteen trading days, triggering an estimated 12 billion USD in index-driven buying. That would instantly make it one of the fund’s top holdings, further concentrating an already top-heavy portfolio.

BlackRock offers two sister ETFs for comparison. The iShares MSCI ACWI fund, at 33.06 billion USD, adds emerging markets, charges 0.32 percent, and has returned 12.14 percent year to date. The iShares Core MSCI Total International Stock ETF (IXUS), the largest of the three at 58.73 billion USD, excludes the US entirely, holds 4,352 positions, costs just 0.07 percent, and is on track for a 14.28 percent annual return. The MSCI World ETF sits in the middle: developed markets only, a heavy US tilt, lower fees than the ACWI, and direct exposure to the mega-caps that IXUS omits entirely.

The next test comes with the US employment report on June 5. Strong job numbers would further extinguish rate-cut hopes, while weak data could extend the tech-driven rally and keep the fund at its record level. For now, the iShares MSCI World ETF is walking a fine line between momentum and overstretch — with a partially open door for an unprecedented SpaceX entry later this year.